Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00206492
(halted by the PI only 3 of 45 subjects were accrued.)
The researchers want to learn whether ZD1839 can improve the activity of tamoxifen, a drug that participants will receive for the treatment of the type of breast cancer being studied. Tamoxifen medicine is part of the standard treatment for the type of breast cancer being studied. It is approved for the treatment of this problem. In order to help the researchers understand how the cancer responds to these medicines, the researchers will take a small tissue sample (biopsy) of the breast cancer before beginning treatment and after two weeks of treatment, at 6 weeks and when surgery is done as part of treatment for the cancer. If participants do not respond to treatment, another biopsy will be done to see why the participants did not respond. These samples will also be collected to look at different characteristics of the cancer. The researchers cannot and do not guarantee that participants will benefit if they take part in this study
mechanisms of the cellular response, markers predicting response, by investigating whether ZD1839 with or without tamoxifen treatment is associated with altered biomarkers in cells isolated by core needle biopsy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All patients must be female and must have signed an informed consent form.
Primary breast cancers must be human epidermal growth factor receptor (HER2) overexpressing (2+ or 3+, or both, as determined by immunohistochemistry [IHC]), and estrogen receptor (ER) positive. Primary breast cancers must be of clinical and/or radiologic size >4 cm, with or without gross metastatic disease according to the International Union against Cancer (UICC) modified World Health Organization (WHO) criteria.
Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential.
Adequate bone marrow function:
total neutrophil count must be >1.5 x 10^9/L, and
platelet count >100 x 10^9/L.
Renal function tests:
creatinine within 1.5 times the institution's upper limit of normal (ULN).
Liver function tests:
Total serum bilirubin within ULN,
liver transaminases within 2.5 x ULN,
alkaline phosphatase within 5 x ULN.
Performance status (WHO scale) <2.
Age > 18 years.
Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.
Women who are lactating or breastfeeding.
Severe underlying chronic illness or disease.
Patients on other investigational drugs while on study will be excluded.
Severe or uncontrolled hypertension, history of congestive heart failure, acute myocardial infarction, or severe coronary arterial disease.
No previous or current malignancies at other sites within the preceding 5 years, with the exception of adequately treated, cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
Any evidence of ongoing interstitial lung disease.
Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.
Known severe hypersensitivity to ZD1839 or any of the excipients of this product.